Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LLG783 in patients with peripheral artery disease and intermittent claudication
2017-000706-37Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in arteriosclerosis obliterans and intermittent claudication (IC) comparing LLG783 with Placebo (2 arms). Primary endpoint: Safety and tolerability of LLG783. Started Aug 2017; status: completed.
02
Drugs
LLG783
03
Conditions
arteriosclerosis obliteransintermittent claudication (IC)
Beyond the preview
Go deeper on 2017-000706-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000706-37.